Analyst Research

Report Title Price
Thomson Reuters Stock Report - BIO-REFERENCE LABORATORIES, INC. (BRLI-O)
Provider: Thomson Reuters Stock Report
$25.00
Buy
ValuEngine Detailed Valuation Report for BRLI
Provider: ValuEngine, Inc.
$127.00
Buy
Bio-Reference Laboratories, Inc. (BRLI) - Medical Equipment - Deals and Alliances Profile
Provider: GlobalData
$250.00
Buy
BIO-REFERENCE LABORATOIRES INC (BRLI) 12-months forecast
Provider: Pechala's Reports
$15.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Bio-Reference Laboratories, Inc. Issues FY 2012 Guidance Above Analysts' Estimates


Thursday, 8 Dec 2011 08:30am EST 

Bio-Reference Laboratories, Inc. announced that for fiscal 2012, it expects to increase net revenues by more than 15% and net income by around 20%. The Company reported revenue of $558.64 million and net profit of $32.63 in fiscal 2011. According to I/B/E/S estimates, analysts were expecting the Company to report revenue of $638 million and net income of $38.23 for fiscal 2012. 

Latest Developments for Bio-Reference Laboratories Inc

Latest Key Developments in Healthcare

Company Quote

Bio-Reference Laboratories Inc
(BRLI.O)
31.07
0.0 +0.00%
3:42pm EDT